Phase I study of Erlotinib and Crizotinib after ALK inhibitor failure in ALK positive advanced Non-Small Cell Lung Cancer
Phase 1
- Conditions
- ALK inhibitor failure in ALK positive advanced Non-Small Cell Lung Cancer
- Registration Number
- JPRN-UMIN000010090
- Lead Sponsor
- Medical thoracic oncology, Cancer institute hospital, Japanese Foundation For Cancer Reseach
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 30
Inclusion Criteria
Not provided
Exclusion Criteria
1)No prior treatment with EGFR-TKI 2)Patients with uncontrollable complications(e.g. uncontrollable heart disease, severe arrhythmia, continuous diarrhea). 3)Patients with active severe brain metastasis. 4)1)Interstitial pneumonia or pulmonary fibrosis detectable on X ray. 5)History of active double cancer within 5 years prior to the study. 6)Patients with symptomatic brain metastasis 7)Impossible cases with oral administration. 8)Pregnancy or lactation 9) Any other medical condition that makes the patient unsuitable for inclusion in the study according to the opinion of the investigator.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method safety
- Secondary Outcome Measures
Name Time Method Response rate, disease control rate, progression free survival, overall Survival,